Ausgabe 1/2015
Inhalt (15 Artikel)
Transforming growth factor-beta and its implication in the malignancy of gliomas
Laurent-Olivier Roy, Marie-Belle Poirier, David Fortin
The status of radioimmunotherapy in CD20+ non-Hodgkin’s lymphoma
Evan D. Read, Peter Eu, Peter J. Little, Terrence J. Piva
QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review
Marzia Locatelli, Carmen Criscitiello, Angela Esposito, Ida Minchella, Aron Goldhirsch, Carlo Cipolla, Giuseppe Curigliano
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
Brian I. Rini, David I. Quinn, Michael Baum, Laura S. Wood, Jamal Tarazi, Brad Rosbrook, Lillian Shahied Arruda, Laura Cisar, W. Gregory Roberts, Sinil Kim, Robert J. Motzer
An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: safety and efficacy with analysis by age group
Esther Tahover, Ayala Hubert, Mark Temper, Azzam Salah, Tamar Peretz, Tamar Hamburger, Beatrice Uziely
Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab
Josep Tabernero, Sant P. Chawla, Hedy Kindler, Karen Reckamp, E. Gabriela Chiorean, Nilofer S. Azad, A. Craig Lockhart, Cheng-Pang Hsu, Nigel F. Baker, Francesco Galimi, Pedro Beltran, José Baselga
Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway
Alexander Gross, Annett Niemetz-Rahn, Anika Nonnenmacher, Johannes Tucholski, Ulrich Keilholz, Alberto Fusi
Study on mouse model of triple-negative breast cancer: association between higher parity and triple-negative breast cancer
Chun Huang, Xuan Wang, Baocun Sun, Man Li, Xiulan Zhao, Yanjun Gu, Yanfen Cui, Yan Li
A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer
Fiona Day, Andrea Muranyi, Shalini Singh, Kandavel Shanmugam, David Williams, David Byrne, Kym Pham, Michelle Palmieri, Jeanne Tie, Thomas Grogan, Peter Gibbs, Oliver Sieber, Paul Waring, Jayesh Desai
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study
Irene Brana, Antonio Calles, Patricia M. LoRusso, Lorrin K. Yee, Thomas A. Puchalski, Shobha Seetharam, Bob Zhong, Carla J. de Boer, Josep Tabernero, Emiliano Calvo
Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer
T. Kogawa, A. Doi, M. Shimokawa, T. M. Fouad, T. Osuga, F. Tamura, T. Mizushima, T. Kimura, S. Abe, H. Ihara, T. Kukitsu, T. Sumiyoshi, N. Yoshizaki, M. Hirayama, T. Sasaki, Y. Kawarada, S. Kitashiro, S. Okushiba, H. Kondo, Y. Tsuji
Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure
Haihong Yang, Xinyun Yang, Yalei Zhang, Xin Liu, Qiuhua Deng, Meiling Zhao, Xin Xu, Jianxing He
Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin’s lymphoma
Gillian M. Keating
Gefitinib: a review of its use in adults with advanced non-small cell lung cancer
Sohita Dhillon
Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma
Hannah A. Blair, Greg L. Plosker